483
Neurocrine Biosciences IncNeurocrine Biosciences Inc – FDA 483, Jul 18, 2024
Record Details
An FDA inspection of Neurocrine Biosciences Inc in San Diego, CA, revealed a significant deficiency in their postmarketing adverse drug experience surveillance. The firm failed to develop adequate written procedures for the receipt and evaluation of safety events, specifically regarding Huntington's Disease. This indicates a lack of robust pharmacovigilance processes.
View Company Profile
ID · 7ea6a782-f76f-4f79-b392-74ad4e8fa5b8
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.